UK markets open in 2 hours 5 minutes

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.3700-0.0100 (-0.72%)
At close: 04:00PM EDT
1.3981 +0.03 (+2.05%)
After hours: 07:57PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 106.75M
Enterprise value -30.66M
Trailing P/E 6.52
Forward P/E 13.70
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.90
Price/book (mrq)5.04
Enterprise value/revenue -0.44
Enterprise value/EBITDA 0.33

Trading information

Stock price history

Beta (5Y monthly) 1.14
52-week change 3-10.46%
S&P500 52-week change 324.71%
52-week high 35.8500
52-week low 31.0400
50-day moving average 32.0950
200-day moving average 31.6963

Share statistics

Avg vol (3-month) 36.65M
Avg vol (10-day) 32.63M
Shares outstanding 577.92M
Implied shares outstanding 678.49M
Float 858.39M
% held by insiders 11.03%
% held by institutions 169.84%
Shares short (15 May 2024) 48.75M
Short ratio (15 May 2024) 40.56
Short % of float (15 May 2024) 411.31%
Short % of shares outstanding (15 May 2024) 411.23%
Shares short (prior month 15 Apr 2024) 43.59M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 13.87%
Operating margin (ttm)28.11%

Management effectiveness

Return on assets (ttm)3.23%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)119.18M
Revenue per share (ttm)1.53
Quarterly revenue growth (yoy)76.40%
Gross profit (ttm)N/A
Net income avi to common (ttm)16.53M
Diluted EPS (ttm)0.2100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)150.28M
Total cash per share (mrq)1.93
Total debt (mrq)12.87M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.16
Book value per share (mrq)-0.47

Cash flow statement

Operating cash flow (ttm)-91.43M
Levered free cash flow (ttm)-471.75k